Abstract
Patients with melanoma who have received ipilimumab appear to be at an increased risk for a drug-hypersensitivity rash when treated with vemurafenib.
Cite
CITATION STYLE
APA
Harding, J. J., Pulitzer, M., & Chapman, P. B. (2012). Vemurafenib Sensitivity Skin Reaction after Ipilimumab. New England Journal of Medicine, 366(9), 866–868. https://doi.org/10.1056/nejmc1114329
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free